Clinical trial
A Single-center, Single-arm, Prospective Clinical Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Platinum-based Chemotherapy and Bayer Aspirin in Previously Untreated Patients With Extensive-stage Small Cell Lung Cancer.
NCT06554535 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Single-arm, Prospective Clinical Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Platinum-based Chemotherapy and Bayer Aspirin in Previously Untreated Patients With Extensive-stage Small Cell Lung Cancer.
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 1, 2024
- Completion date
- October 1, 2027
- Enrollment
- 43 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
ecog performance status score of 0 or 1, expected survival ≥3 months, extensive-stage small cell lung cancer, treatment-naïve for systemic therapy targeting extensive-stage small cell lung cancer